Characteristics, Trends, and Outcomes of Liver Transplantation for Primary Sclerosing Cholangitis in Female Versus Male Patients: An Analysis From the European Liver Transplant Registry

Supplemental Digital Content is available in the text. Background. The influence of sex on primary sclerosing cholangitis (PSC), pre- and postliver transplantation (LT) is unclear. Aims are to assess whether there have been changes in incidence, profile, and outcome in LT-PSC patients in Europe with specific emphasis on sex. Methods. Analysis of the European Liver Transplant Registry database (PSC patients registered before 2018), including baseline demographics, donor, biochemical, and clinical data at LT, immunosuppression, and outcome. Results. European Liver Transplant Registry analysis (n = 6463, 32% female individuals) demonstrated an increasing number by cohort (1980–1989, n = 159; 1990–1999, n = 1282; 2000–2009, n = 2316; 2010–2017, n = 2549) representing on average 4% of all transplant indications. This increase was more pronounced in women (from 1.8% in the first cohort to 4.3% in the last cohort). Graft survival rate at 1, 5, 10, 15, 20, and 30 y was 83.6%, 70.8%, 57.7%, 44.9%, 30.8%, and 11.6%, respectively. Variables independently associated with worse survival were male sex, donor and recipient age, cholangiocarcinoma at LT, nondonation after brain death donor, and reduced size of the graft. These findings were confirmed using a more recent LT population closer to the current standard of care (LT after the y 2000). Conclusions. An increasing number of PSC patients, particularly women, are being transplanted in European countries with better graft outcomes in female recipients. Other variables impacting outcome include donor and recipient age, cholangiocarcinoma, nondonation after brain death donor, and reduced graft size.

[1]  J. Korzenik,et al.  Fecal Microbiota Transplantation in Patients With Primary Sclerosing Cholangitis: A Pilot Clinical Trial. , 2019, The American journal of gastroenterology.

[2]  K. Lindor,et al.  Characteristics and Outcomes Reported by Patients With Primary Sclerosing Cholangitis Through an Online Registry. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[3]  P. Trivedi,et al.  Systematic review with meta‐analysis: risk factors for recurrent primary sclerosing cholangitis after liver transplantation , 2019, Alimentary pharmacology & therapeutics.

[4]  C. Schramm,et al.  Sex-related factors in autoimmune liver diseases , 2018, Seminars in Immunopathology.

[5]  P. Schirmacher,et al.  Impact of age at diagnosis on disease progression in patients with primary sclerosing cholangitis , 2018, United European gastroenterology journal.

[6]  T. Karlsen,et al.  Primary sclerosing cholangitis - a comprehensive review. , 2017, Journal of hepatology.

[7]  M. Manns,et al.  Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. , 2017, Gastroenterology.

[8]  T. Karlsen,et al.  Genetics of primary sclerosing cholangitis and pathophysiological implications , 2017, Nature Reviews Gastroenterology &Hepatology.

[9]  S. Chow,et al.  Differences in Phenotypes and Liver Transplantation Outcomes by Age Group in Patients with Primary Sclerosing Cholangitis , 2017, Digestive Diseases and Sciences.

[10]  W. Lieb,et al.  Faecal microbiota profiles as diagnostic biomarkers in primary sclerosing cholangitis , 2016, Gut.

[11]  J. Raes,et al.  Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD , 2016, Gut.

[12]  C. Constantinidou,et al.  The gut-adherent microbiota of PSC–IBD is distinct to that of IBD , 2016, Gut.

[13]  Aly A. Khan,et al.  Gender bias in autoimmunity is influenced by microbiota. , 2013, Immunity.

[14]  G. Alexander,et al.  Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. , 2013, Gastroenterology.

[15]  A. Burroughs,et al.  Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). , 2012, Journal of hepatology.

[16]  C. Ponsioen,et al.  Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. , 2012, Journal of hepatology.

[17]  Y. Nakanuma,et al.  Risk Factors for Recurrence of Primary Sclerosing Cholangitis after Living Donor Liver Transplantation in Japanese Registry , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[18]  M. Sebagh,et al.  Recurrence of autoimmune disease, primary sclerosing cholangitis, primary biliary cirrhosis, and autoimmune hepatitis after liver transplantation , 2009, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[19]  J. Neuberger,et al.  A re‐evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts , 2009, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[20]  J. Neuberger,et al.  The impact of disease recurrence on graft survival following liver transplantation: a single centre experience , 2008, Transplant international : official journal of the European Society for Organ Transplantation.

[21]  J. Trotter,et al.  Clinically recurrent primary sclerosing cholangitis following liver transplantation: A time course , 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[22]  M. Yeh,et al.  Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation , 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[23]  C. Sabin,et al.  3-month and 12-month mortality after first liver transplant in adults in Europe: predictive models for outcome , 2006, The Lancet.

[24]  J. Neuberger,et al.  Risk factors for recurrence of primary sclerosing cholangitis of liver allograft , 2002, The Lancet.

[25]  K. Watt,et al.  The Intestinal Microbiome and the Liver Transplant Recipient: What We Know and What We Need to Know. , 2016, Transplantation.

[26]  B. Portmann,et al.  Impact of gender on the long-term outcome and survival of patients with autoimmune hepatitis. , 2008, Journal of hepatology.